Evidence map›Paper›PMID 37865795›Full record

ArticleStem cell research & therapy2023

Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent.

Mikhail Svistushkin, Anastasia Shpichka, Polina Bikmulina, Alexey Fayzullin, Anna Zolotova, Nastasia Kosheleva, Liliya Selezneva, Boris Shavkuta, Viktoria Lobacheva, Anna Nikiforova and 7 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. A hybrid vocal fold phonatory platform for pediatric phonation modeling.Frontiers in bioengineering and biotechnology · 2025
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 2 countries.

Mikhail SvistushkinDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Anastasia ShpichkaInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Polina BikmulinaInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Alexey FayzullinInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Anna ZolotovaDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Nastasia KoshelevaInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Liliya SeleznevaDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Boris ShavkutaInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Viktoria LobachevaDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Anna NikiforovaDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Peter KochetkovDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Svetlana KotovaInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Svetlana StarostinaDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Anatoly ShekhterInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Andrey SvistunovSechenov University, Moscow, Russia.
Valeriy SvistushkinDepartment for ENT Diseases, Sechenov University, Moscow, Russia.
Peter TimashevInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia. timashev_p_s@staff.sechenov.ru.ORCID 0000-0001-7773-2435
Sechenov University · RU

Funding

Russian Science Foundation 21-15-00339
6 · The paper itself

Abstract

backgroundThere is growing interest to application of regenerative medicine approaches in otorhinolaryngological practice, especially in the framework of the therapy of vocal fold (VF) scar lesions. The used conservative and surgical methods, despite the achieved positive outcomes, are frequently unpredictable and do not result in the restoration of the VF's lamina propria's structure, which provides the mechanical properties necessary for vibration. In this connection, the aim of this study was to ascertain the safety and efficacy of a bioequivalent in the treatment of VF scars using a rabbit model of chronic damage.

methodsThe bioequivalent consisted of a hydrogel system based on a PEG-fibrin conjugate and human bone marrow-derived MSC. It was characterized and implanted heterotopically into rats and orthotopically into rabbits after VF scar excision.

resultsWe showed that the fabricated bioequivalent consisted of viable cells retaining their metabolic and proliferative activity. While being implanted heterotopically, it had induced the low inflammatory reaction in 7 days and was well tolerated. The orthotopic implantation showed that the gel application was characterized by a lower hemorrhage intensity (p = 0.03945). The intensity of stridor and respiratory rate between the groups in total and between separate groups had no statistically significant difference (p = 0.96 and p = 1; p = 0.9593 and p = 0.97…1, respectively). In 3 days post-implantation, MSC were detected only in the tissues closely surrounding the VF defect. The bioequivalent injection caused that the scar collagen fibers were packed looser and more frequently mutually parallel that is inherent in the native tissue (p = 0.018). In all experimental groups, the fibrous tissue's ingrowth in the adjacent exterior muscle tissue was observed; however, in Group 4 (PEG-Fibrin + MSC), it was much less pronounced than it was in Group 1 (normal saline) (p = 0.008). The difference between the thicknesses of the lamina propria in the control group and in Group 4 was not revealed to be statistically significant (p = 0.995). The Young's modulus of the VF after the bioequivalent implantation (1.15 ± 0.25 kPa) did not statistically significantly differ from the intact VF modulus (1.17 ± 0.45 kPa); therefore, the tissue properties in this group more closely resembled the intact VF.

conclusionsThe developed bioequivalent showed to be biocompatible and highly efficient in the restoration of VF's tissue.

Indexed as

CicatrixMesenchymal Stem Cell TransplantationAnimalsFibrinHumansRabbitsRatsRegenerative MedicineVocal CordsFibrinBioequivalentFibrinIn vivoMesenchymal stromal cellsPEG-fibrinRegenerative medicineScarringTissue engineeringVocal folds

Identifiers

PMID37865795
PMCPMC10590531
OpenAlexW4387844649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.